ArticleFrontiers in oncology2022

Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma.

Stefano Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.